Format
Items per page
Sort by

Send to:

Choose Destination

Results: 6

Cited In for PubMed (Select 20008977)

1.

PET imaging in prostate cancer: focus on prostate-specific membrane antigen.

Mease RC, Foss CA, Pomper MG.

Curr Top Med Chem. 2013;13(8):951-62. Review.

2.

Functional imaging for prostate cancer: therapeutic implications.

Mari Aparici C, Seo Y.

Semin Nucl Med. 2012 Sep;42(5):328-42. doi: 10.1053/j.semnuclmed.2012.04.004. Review.

3.

Combined SPECT and Multidetector CT for Prostate Cancer Evaluations.

Aparici CM, Carlson D, Nguyen N, Hawkins RA, Seo Y.

Am J Nucl Med Mol Imaging. 2012;2(1):48-54.

4.

Recent trends in antibody-based oncologic imaging.

Kaur S, Venktaraman G, Jain M, Senapati S, Garg PK, Batra SK.

Cancer Lett. 2012 Feb 28;315(2):97-111. doi: 10.1016/j.canlet.2011.10.017. Epub 2011 Oct 20. Review.

5.

Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT.

Schuster DM, Savir-Baruch B, Nieh PT, Master VA, Halkar RK, Rossi PJ, Lewis MM, Nye JA, Yu W, Bowman FD, Goodman MM.

Radiology. 2011 Jun;259(3):852-61. doi: 10.1148/radiol.11102023. Epub 2011 Apr 14.

6.

Prostate specific membrane antigen- a target for imaging and therapy with radionuclides.

Bouchelouche K, Choyke PL, Capala J.

Discov Med. 2010 Jan;9(44):55-61.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk